Immunogenic oncolysis by tigilanol tiglate

Jonathan Pol; Manuela Lizarralde-Guerrero; Guido Guido Kroemer

doi:10.1080/2162402x.2024.2360230

Abstract

1 min read

Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Editorial Material2023

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Lucillia Bezu, Oliver Kepp, Guido Guido Kroemer

Article2019

Tumor lysis with LTX-401 creates anticancer immunity

Wei Xie, Laura Mondragón, Brynjar Mauseth, Yan Wang, Jonathan Pol, Sarah Lévesque, Heng Zhou, Takahiro Yamazaki, J. Johannes Eksteen, Laurence Zitvogel, Baldur Sveinbjørnsson, Øystein Rekdal, Oliver Kepp, Guido Guido Kroemer

Article2017

Abstract 4563: Local and abscopal effects in oncolytic virotherapy are boosted by immune checkpoint blockade, immunogenic chemotherapy, or IFNAR blockade

Laetitia Fend, Takahiro Yamazaki, Xavier Préville, Éric Quéméneur, Oliver Kepp, Julien Adam, Aurélien Marabelle, Jonathan M. Pitt, Guido Guido Kroemer, Laurence Zitvogel

Article2022

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer

Peng Liu, Jianzhou Chen, Liwei Zhao, Antoine Hollebecque, Oliver Kepp, Laurence Zitvogel, Guido Guido Kroemer

Editorial Material2021

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade

Guido Guido Kroemer, Oliver Kepp